Day: May 12, 2025

FDA Meeting for Tanruprubart (formerly ANX005), the First Potential Targeted Therapy for GBS, Scheduled for Second Quarter 2025 Ahead of Planned BLA Submission Open-Label Tanruprubart FORWARD Study Designed to Broaden Patient and Healthcare Community Experience in North America and Europe, Initiating in Second Quarter 2025 Accelerated Enrollment in Phase 3 ARCHER II Trial on Pace for Completion in Third Quarter 2025 for ANX007, the First Potential Treatment for Dry AMD with GA; Pivotal Topline Data Expected in the Second Half of 2026 Completion of Proof-of-Concept Trial for First-in-Kind Oral C1s Inhibitor ANX1502 in Cold Agglutin Disease Anticipated Mid-2025; Potential to Disrupt the Current Treatment of Antibody-Mediated Autoimmune Diseases $263.7 million in Cash, Cash Equivalents, and Short-term Investments as of March 31, 2025 Funds...

Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB) Plan to initiate Phase 3 trial of neflamapimod in DLB in mid-2026 following meeting with regulatory authorities Initiating separate Phase 2a trials to evaluate neflamapimod in patients with primary progressive aphasia and patients in the recovery phase after ischemic stroke BOSTON, May 12, 2025 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today reported its financial results for the first quarter ended March 31, 2025. “The first quarter of 2025 represented a tidal shift for CervoMed. We believe the evidence...

Successful completion of €30 Million capital increase, with strong international demand and oversubscription Awarded non-refundable EU grant of €13.26 Million through the first Important Project of Common European Interest (IPCEI) in the health sector (Med4Cure project) Vafidemstat’s Phase III PORTICO-2 trial endpoints for agitation and aggression in BPD defined with input from new Clinical Advisory Board; finalizing preparations for Phase III Results of observational clinical study on Phelan-McDermid syndrome patients published in Frontiers in Psychiatry Continues to enroll patients in Phase IIb EVOLUTION trial with vafidemstat in schizophrenia First patient dosed in NCI-sponsored Phase I/II study of iadademstat plus immune checkpoint inhibitors in 1L extensive stage Small Cell Lung Cancer First cohort dosed in Phase I/II study of...

VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) — Conifex Timber Inc. (“Conifex”, “we” or “us”) (TSX: CFF) today reported results for the first quarter ended March 31, 2025. EBITDA* was $4.9 million for the quarter compared to EBITDA of negative $2.1 million in the fourth quarter of 2024 and negative $0.5 million in the first quarter of 2024. Net income was $0.6 million or $0.02 per share for the quarter versus net loss of $7.8 million or $0.19 per share in the previous quarter and negative $4.5 million or $0.11 per share in the first quarter of 2024. Selected Financial Highlights The following table summarizes our selected financial information for the comparative periods. The financial information reflects results of operations from our Mackenzie sawmill and power plant.  Selected Financial Information      (unaudited,...

Topline results for the Phase 2 Avail™ evaluating canvuparatide in patients with hypoparathyroidism expected in 3Q 2025 Investigational New Drug submission for MBX 4291 on track for 2Q 2025 $240.8 million in cash, cash equivalents and marketable securities as of March 31, 2025; expected to support operations into mid-2027 CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) — MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent corporate progress. “We’ve followed up on our strong execution in 2024 with excellent progress on all our programs enabled by a strong balance sheet...

First Half Fiscal 2025 Revenue Growth and Positive Cash from Operations Outpace Prior Year Period ASHLAND, Ky., May 12, 2025 (GLOBE NEWSWIRE) — TX Rail Products, Inc. (OTC Markets PINK: TXRP), a supplier of rail and rail products to the U.S. coal mining industry, short line railroads and tunneling contractors, today announced financial results for the second quarter of fiscal year 2025. Mr. Shrewsbury, CEO and Chairman of TX Rail Products, Inc., commented, “Through the first half of fiscal 2025, we outpaced the same period last year with higher revenue and increased cash from operations. With strong demand signals across our key markets and favorable market conditions for our offerings, we are entering the second half of the year with confidence.” Second Quarter Fiscal Year 2025 Financial Summary Revenue for the second fiscal...

BRENTWOOD, Tenn., May 12, 2025 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical facility owner and operator, today announced results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Highlights(All comparisons are year-over-year unless otherwise noted)Revenue increased 8.2% for the first quarterSame-facility revenues increased 5.2% for the first quarter Same-facility cases increased 6.5% for the first quarterNet loss attributable to Surgery Partners, Inc. was $37.7 million for the first quarterAdjusted EBITDA increased 6.6% to $103.9 million for the first quarter2025 GuidanceFull year 2025 revenue and Adjusted EBITDA guidance reaffirmed to be in the range of $3.30 billion to $3.45 billion and $555 million to $565 million,...

First Quarter Chubbies Segment Sales up 43.9% and Solo Stove Sales Down, as Expected, to Realign Go-to-Market Strategy; Solid Evidence of Transformation Traction in the Quarter GRAPEVINE, Texas, May 12, 2025 (GLOBE NEWSWIRE) — Solo Brands, Inc. (NYSE: DTC; OTC: DTCB)(1) (“Solo Brands” or “the Company”) a leading portfolio of lifestyle brands (Solo Stove, Chubbies, Isle and Oru) that are redefining the outdoor and apparel industries, today announced its financial results for the three months ended March 31, 2025. John Larson, Interim President and Chief Executive Officer, commented, “The first quarter’s performance reflected strong sales from the Chubbies segment, up 44% from a year ago, generating segment EBITDA of 26.5% of net sales. We are pleased with Chubbies’ strong consumer engagement and demand. Solo Stove first quarter...

VANCOUVER, British Columbia, May 12, 2025 (GLOBE NEWSWIRE) — Imperial Metals Corporation (the “Company”) (TSX:III) reports financial results for the three months ended March 31, 2025. QUARTER HIGHLIGHTS “Imperial delivered solid operating and financial results for the first quarter of 2025”, said Brian Kynoch, President. “Consolidated production totalled 15,842,336 pounds copper and 17,120 ounces gold which was higher by 28% and 33% respectively, compared to the first quarter of 2024. Financially, we achieved strong operating cash flows of $68.3 million along with revenues of $176.6 million and adjusted EBITDA of $97.7 million.” FINANCIAL Total revenue was $176.6 million in the March 2025 quarter compared to $84.6 million in the 2024 comparative quarter. In the March 2025 quarter, Mount Polley mine had 1.9 concentrate shipments...